Parcion Private Wealth LLC Grows Holdings in Abbott Laboratories (NYSE:ABT)

Parcion Private Wealth LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 3.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,187 shares of the healthcare product maker's stock after acquiring an additional 2,161 shares during the period. Parcion Private Wealth LLC's holdings in Abbott Laboratories were worth $7,713,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Advyzon Investment Management LLC purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth $335,000. Wealth Alliance grew its position in Abbott Laboratories by 5.8% during the 4th quarter. Wealth Alliance now owns 13,119 shares of the healthcare product maker's stock valued at $1,484,000 after purchasing an additional 716 shares during the last quarter. LMG Wealth Partners LLC increased its stake in Abbott Laboratories by 3.8% during the 4th quarter. LMG Wealth Partners LLC now owns 2,161 shares of the healthcare product maker's stock valued at $244,000 after purchasing an additional 80 shares in the last quarter. Jacobson & Schmitt Advisors LLC raised its holdings in Abbott Laboratories by 2.9% in the fourth quarter. Jacobson & Schmitt Advisors LLC now owns 2,827 shares of the healthcare product maker's stock worth $320,000 after buying an additional 80 shares during the last quarter. Finally, Corps Capital Advisors LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $588,000. Institutional investors own 75.18% of the company's stock.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the transaction, the executive vice president now directly owns 125,697 shares of the company's stock, valued at $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.10% of the stock is owned by insiders.

Abbott Laboratories Price Performance

Abbott Laboratories stock traded up $1.87 during midday trading on Friday, reaching $135.04. 6,840,167 shares of the stock traded hands, compared to its average volume of 6,509,540. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $135.41. The stock's fifty day moving average is $120.32 and its 200-day moving average is $116.65. The stock has a market cap of $234.22 billion, a P/E ratio of 17.65, a PEG ratio of 2.46 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, meeting analysts' consensus estimates of $1.34. The firm had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Abbott Laboratories's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the firm posted $1.19 earnings per share. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.75%. Abbott Laboratories's dividend payout ratio is 30.85%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ABT shares. Argus raised Abbott Laboratories to a "strong-buy" rating in a research report on Tuesday, January 28th. Royal Bank of Canada reissued an "outperform" rating and set a $135.00 price objective on shares of Abbott Laboratories in a report on Tuesday, January 21st. Barclays reissued an "overweight" rating and set a $158.00 price target (up from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Stifel Nicolaus raised their target price on Abbott Laboratories from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Finally, Evercore ISI lifted their price target on shares of Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a research note on Thursday, January 2nd. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $133.06.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.